Want to see SE:DVYSR full AI Analyst Report?

Devyser Diagnostics AB (DVYSR) Price & Analysis

1 Followers

DVYSR Stock Chart & Stats

kr58.90

kr0.40(0.59%)

At close: Jul 29 4:00 PM EDT

kr58.90

kr0.40(0.59%)

Day’s Range― - ―

52-Week Rangekr52.90 - kr159.60

Previous CloseN/A

Volume16.23K

Average Volume (3M)12.90K

Market Cap

kr925.56M

Enterprise Valuekr1.41K

Total Cash (Recent Filing)kr81.00M

Total Debt (Recent Filing)kr45.80M

Price to Earnings (P/E)58.2

Beta0.60

Next Earnings

Nov 03, 2026

EPS Estimate

0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.92

Shares Outstanding16,889,807

10 Day Avg. Volume9,471

30 Day Avg. Volume12,897

Financial Highlights & Ratios

PEG Ratio2.59

Price to Book (P/B)5.35

Price to Sales (P/S)7.56

P/FCF Ratio282.82

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.6

Revenue Forecast (FY)kr245.80M

Bulls Say, Bears Say

Bulls Say

Profitability InflectionThe return to profitability, supported by strong gross margins and positive operating margins, indicates meaningful improvement in the economics of Devyser’s diagnostic products. If sustained, this gives the company greater capacity to reinvest in assays, commercial expansion, and laboratory adoption over the coming quarters.

Low LeverageA conservatively levered balance sheet reduces financial pressure and preserves flexibility while the company continues improving profitability. The sizeable equity base relative to debt should help Devyser fund operations and strategic initiatives with less exposure to interest burdens or refinancing constraints.

Positive Cash GenerationThe shift to positive operating and free cash flow is an important sign that the business is beginning to generate internal funding rather than relying entirely on external capital. Continued cash generation would strengthen resilience and support product development, commercialization, and working-capital needs.

Bears Say

Revenue DeclineLower trailing revenue shows that the earnings recovery has not yet been accompanied by consistent top-line expansion. Without renewed demand, broader laboratory adoption, or higher utilization of Devyser’s assay portfolio, margin gains may have limited room to compound and could be harder to sustain.

Weak Cash ConversionAlthough cash flow is positive, the reported conversion ratio indicates that accounting earnings are not translating fully into free cash generation. This weakens the quality of the current turnaround, limits internally funded growth relative to reported profit, and leaves execution on cash conversion important over the next several quarters.

Modest ReturnsThe improvement to positive return on equity is encouraging, but a roughly 4.3% level remains modest and follows losses in earlier periods. This suggests that the business has not yet demonstrated strong, durable productivity from its capital base, leaving further operating improvement necessary to establish more robust returns.

DVYSR FAQ

What was Devyser Diagnostics AB’s price range in the past 12 months?

Devyser Diagnostics AB lowest stock price was kr52.90 and its highest was kr159.60 in the past 12 months.

What is Devyser Diagnostics AB’s market cap?

Devyser Diagnostics AB’s market cap is kr925.56M.

When is Devyser Diagnostics AB’s upcoming earnings report date?

Devyser Diagnostics AB’s upcoming earnings report date is Nov 03, 2026 which is in 45 days.

How were Devyser Diagnostics AB’s earnings last quarter?

Devyser Diagnostics AB released its earnings results on Jul 20, 2026. The company reported kr0.1 earnings per share for the quarter, missing the consensus estimate of kr0.393 by -kr0.293.

Is Devyser Diagnostics AB overvalued?

According to Wall Street analysts Devyser Diagnostics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Devyser Diagnostics AB pay dividends?

Devyser Diagnostics AB does not currently pay dividends.

What is Devyser Diagnostics AB’s EPS estimate?

Devyser Diagnostics AB’s EPS estimate is 0.05.

How many shares outstanding does Devyser Diagnostics AB have?

Devyser Diagnostics AB has 16,889,807 shares outstanding.

What happened to Devyser Diagnostics AB’s price movement after its last earnings report?

Devyser Diagnostics AB reported an EPS of kr0.1 in its last earnings report, missing expectations of kr0.393. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Devyser Diagnostics AB?

Currently, no hedge funds are holding shares in SE:DVYSR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Devyser Diagnostics AB

Headquartered in Hägersten, Sweden, and established in 2004, Devyser Diagnostics AB (publ) specializes in the development, manufacturing, and global sale of advanced diagnostic kits and solutions for DNA testing. The company's innovative products are crucial for genetic analysis in key medical areas, including hereditary diseases, oncology, and post-transplantation monitoring. Devyser offers a broad array of diagnostic tools, covering applications such as post-transplant management, thalassemia screening, and the detection of various cancers like breast, colorectal, and ovarian. Their portfolio also extends to non-invasive fetal RHD screening, diagnostics for inherited conditions, cystic fibrosis, cardiovascular issues, male infertility, and rapid aneuploidy analysis, complemented by essential accessories. These solutions are utilized for diverse purposes, from diagnosing genetic disorders and guiding targeted cancer treatments to ensuring thorough follow-up care for transplant patients. Furthermore, Devyser provides specialized software programs, including Amplicon Suite and Advyser, which facilitate the processing, analysis, and interpretation of test results, enabling efficient marker screening and patient sample tracking. The company's operations span Sweden, the broader European market, the Middle East, Africa, North and South America, and Asia.